Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology

• US 6,287,792 B1
• Filed: 06/17/1991
• Issued: 09/11/2001
• Est. Priority Date: 06/17/1991
• Status: Expired due to Term

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Boado, Ruben J., Pardridge, William M.
• Primary Examiner(s): Allen, Marianne P.
• Application Number:
  US07/716,062
• Time in Patent Office: 3,739 Days
• Field of Search: 436/532, 435/6, 435/7.5, 435/7.9, 424/85, 424/88, 530/387.1, 530/324, 530/350, 530/399, 536/23.1, 536/23.5
• US Class Current: 435/7.5
• CPC Class Codes: A61K 47/665 the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
• CPC Class Codes: A61K 47/6898 using avidin- or biotin-conjugated antibodies
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/465 from birds
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/22 containing a Strep-tag
• CPC Class Codes: C07K 2319/33 fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• CPC Class Codes: C07K 7/16 Oxytocins; Vasopressins; Related peptides
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/335 Modified T or U
• CPC Class Codes: C12N 2310/3513 Protein; Peptide
• CPC Class Codes: C12N 2310/3535 Nitrogen

Abstract

A composition for delivering an agent to cells in vitro or to tissues or organs in vivo. The composition comprises either avidin or an avidin fusion protein bonded to a biotinylated agent to form an avidin-biotin-agent complex. A method is further provided for delivering an agent to cells using the avidin-biotin-agent complex which involves administering the complex to an individual subject. The avidin-biotin-agent complex is used in therapeutic and diagnostic methods.

Claims

1. A composition for delivery of an agent to cells, said composition consisting of:

a transport vector comprising an avidin moiety;

at least one monobiotinylated agent bonded to said avidin moiety via an avidin-biotin linkage to provide an avidin-biotin-agent complex; and

a pharmaceutically acceptable carrier.

2. The composition of claim 1 wherein the monobiotinylated agent comprises a pharmaceutical compound selected from the group consisting of monobiotinylated peptides, antisense oligonucleotides, immunoglobulins, and organic chemicals.

3. The composition of claim 1 wherein the monobiotinylated agent comprises a diagnostic compound selected from the group consisting of monobiotinylated immunoglobulins, oligonucleotides, amyloid ligands, and receptor ligands.

4. The composition of claim 1 wherein the monobiotinylated agent is selected from the group consisting of monobiotinylated oligonucleotides, polypeptides, immunoglobulins, and organic chemicals.